|
ToxiPharm LLC
ToxSignal
Clinical Toxicology Intelligence
|
Issue
#09
July 2026
|
|
|
|
Hi *|FNAME|*,
The DEA made an important move on July 1: filing Notices of Intent to temporarily place concentrated 7-hydroxymitragynine (7-OH) products into Schedule I. If you work with patients who use "enhanced" kratom products, that change is coming within weeks, and most testing programs cannot currently distinguish concentrated 7-OH from natural kratom leaf analytically. This issue leads with what that distinction means and what it does not.
Also: the DEA marijuana rescheduling hearing wraps July 15, a new Virginia law targeting inhalant misuse took effect July 1, and a new network meta-analysis makes the strongest pooled case yet for extended-release buprenorphine when retention is the goal.
|
|
|
◆ Drug Trend Spotlight
|
KRATOM / 7-HYDROXYMITRAGYNINE
|
DEA Moved to Schedule I Concentrated 7-OH Products on July 1. Natural Kratom Leaf Is Carved Out.
On July 1, 2026, the DEA filed Notices of Intent to temporarily place 7-hydroxymitragynine (7-OH) above 0.050% dry weight, along with three synthetic analogs (mitragynine pseudoindoxyl, MGM-15, and MGM-16), into Schedule I of the Controlled Substances Act. HHS and FDA backed the action publicly the same day. ASAM issued a policy statement supporting stronger regulation of enhanced kratom products. A 30-day waiting period applies before the temporary order can take effect, as early as August 2026.
The distinction the order draws is clinically important and analytically challenging. Natural kratom leaf and preparations where 7-OH is present below the 0.050% threshold remain outside federal scheduling. The target is the "enhanced" format: concentrated tablets, shots, and extracts sold at gas stations and supplement retailers, often labeled as containing elevated 7-OH. These products have a materially different pharmacological and withdrawal profile than leaf kratom, and a 2026 case report documents a patient developing pulseless ventricular tachycardia after concentrated kratom extract ingestion.
The practical challenge for OTPs, drug courts, and testing programs: standard mitragynine immunoassays do not differentiate concentrated 7-OH from natural leaf. Distinguishing the two analytically requires LC-MS/MS with 7-OH-specific quantitation. Once the order takes effect, MROs and program staff will also need updated reporting guidance to avoid treating a natural kratom result as a Schedule I positive.
|
Why it matters
If a patient in your program uses enhanced kratom products, those products will carry Schedule I status within the next several weeks. Most current urine testing panels cannot make the natural leaf vs. concentrated 7-OH distinction without LC-MS/MS and 7-OH quantitation. Now is the time to review what your lab reports for kratom-positive specimens and what your program's policy says, before the order takes effect.
|
U.S. Drug Enforcement Administration. Notices of Intent to Temporarily Schedule 7-Hydroxymitragynine and Related Substances. July 1, 2026. · American Society of Addiction Medicine. ASAM Supports Strong Health and Safety Regulation of Kratom Products. July 1, 2026.
|
|
|
|
|
◆ Regulatory & Policy Update
| |
Deadline: July 15, 2026
DEA Marijuana Rescheduling Hearing Must Conclude by July 15. Watch for Rulemaking Timeline After.
The expedited DEA administrative hearing on moving marijuana from Schedule I to Schedule III reconvened July 6 and must conclude by July 15 under the court-ordered schedule. The hearing closes the evidentiary record; it does not produce rescheduling. Any final rule would require separate DEA action and additional rulemaking, and could take months or longer.
For drug testing programs, the practical implications of a Schedule III classification remain limited: federal workplace testing requirements and program-level marijuana prohibitions would not change automatically. Watch for post-hearing DEA guidance on projected rulemaking timelines after July 15.
|
| |
Effective: July 1, 2026 (Virginia)
Virginia Bans Sale of Nitrous Oxide Containers Over 8 Grams Intended for Inhalant Misuse.
A new Virginia law effective July 1, 2026, prohibits the sale or distribution of nitrous oxide containers exceeding 8 grams when intended for inhalant misuse. The law targets the large-capacity "whippet" canisters that have circulated at recreational events. For Virginia OTP and drug court clinicians: nitrous oxide is not detectable on standard UDT panels; the new law is a supply-side intervention, not a testing one. Awareness of nitrous oxide use patterns remains relevant for clinical history-taking when patients present with unexplained neurological symptoms.
|
|
|
|
|
◆ Science Worth Reading
|
SYSTEMATIC REVIEW / NETWORK META-ANALYSIS
Extended-Release Buprenorphine Shows the Highest Probability of Retention and Abstinence in New Network Meta-Analysis.
A 2026 systematic review and network meta-analysis pooling data from RCTs and observational studies across OUD pharmacotherapies found that extended-release buprenorphine (BUP-XR) had the highest probability of both treatment retention and opioid abstinence among all therapies compared. The analysis provides the strongest pooled evidence to date for XR formulations as the preferred option when adherence, diversion risk, or supervised dosing logistics are clinical considerations.
The finding is relevant beyond clinical preference: prior authorization denials for BUP-XR in favor of daily oral formulations remain common, and the network meta-analytic retention and abstinence data are the evidence base for pushing back on those denials.
|
My Take
The clinical case for extended-release buprenorphine has been clear for years. The obstacle is rarely the evidence; it is payer barriers and formulary restrictions. This systematic review gives you the meta-analytic retention and abstinence data to put in front of a payer when they try to substitute a daily oral formulation. Use it for prior authorization appeals. It is the kind of evidence that belongs in every OTP's formulary justification documentation.
|
Systematic review and network meta-analysis of OUD pharmacotherapies. PubMed 41521864. 2026.
|
|
|
|
From Bill
"Two stories this week that illustrate the same gap: the gap between what the policy label says and what actually changes in practice. The 7-OH scheduling action matters. Concentrated kratom products are genuinely more dangerous than leaf kratom, and drawing a regulatory threshold is the right call. But patients currently using enhanced products are not going to stop, most programs can't make the distinction analytically right now, and the MRO reporting guidance doesn't exist yet. Knowing that a rule is coming and being ready for it are different problems. The BUP-XR data is the other side: the evidence for extended-release formulations over daily oral dosing has been solid for years, and payer barriers persist anyway. In both cases, the clinical gap is not information. It is infrastructure."
Dr. William Bundy Jr., PharmD
Clinical Toxicologist & Consultant · ToxiPharm LLC
|
|
ToxiPharm LLC
Clinical toxicology consulting, expert review, UDT interpretation, and Tox In Focus clinical references.
toxipharm.org
|
|
Clinical Disclaimer
Content in this newsletter is intended for clinical reference and educational purposes for use by qualified clinicians, medical review officers, and drug program administrators. It does not represent an all-inclusive review of available evidence. Clinical data, regulatory guidance, and laboratory standards evolve; readers should verify current requirements with applicable authorities. Content in this newsletter does not constitute medical, legal, or regulatory advice and should not replace independent clinical judgment. ToxiPharm LLC makes no warranties regarding completeness or applicability in all clinical situations. © 2026 ToxiPharm LLC · toxipharm.org
|
|
ToxiPharm LLC · Clinical Toxicology & Regulatory Consulting
ToxSignal is a clinical toxicology newsletter from ToxiPharm LLC. Subscribe at toxipharm.org.
All ToxSignal issues
·
ToxiPharm home
*|HTML:LIST_ADDRESSLINE|*
Update preferences
·
Unsubscribe
|
|